Dec
18
2018
On demand

Evaluation of Poros AAVX Pan-Affinity Resin for rAAV purification and cGMP Manufacturing

Affinity interaction based resins are the foundation for the platform purification of many different biological molecules. While some AAV affinity resins have existed for more than a decade, the growth in the AAV field now demands a true pan-affinity workhorse, analogous to Protein A for mAbs. In this work, Daniel Hurwit, Voyager Therapeutics, investigates POROS CaptureSelect AAVX (AAVX) for the purification of various serotypes from both crude and pure feed streams. Performance of AAVX is directly compared against other commercially available AAV affinity resins for qualities such as binding capacities, binding kinetics, product recovery, impurity clearance, washing and elution strategies, cleanability, cyclability, regeneration as well as the scalability and suitability of the new resin for commercial manufacturing. The results demonstrate that the new AAVX resin is a robust option for the scalable, platform purification of various rAAV capsids from crude feed streams. 

Watch this On Demand Webinar with Daniel Hurwit, Process Development, Voyager Therapeutics to hear about:

  • The history, development, and mechanism of action of AAV affinity resins;
  • Comparability of the leading AAV affinity resins across numerous serotypes in regard to binding kinetics, binding capacities, product recovery and purity, and suitability for large-scale manufacturing;
  • Easily implementable high-throughput approaches to chromatographic development.

Daniel Hurwit, Senior Associate Engineer, Voyager Therapeutics

Dan is a Senior Associate Engineer at Voyager Therapeutics (Cambridge, MA) focused on rAAV purification process development, technical operations and CMC. Dan earned his Bachelors in Physics and Masters in Biological Engineering from Tufts University. Prior to Voyager Dan worked on purification process development of multitudinous recombinant proteins.


SPEAKERS

Daniel Hurwit
Scientist at Bristol-Myers Squibb

You might also like

Thinking translational: Things to consider in CAR T cell research workflows

S Rösch, PhD
Saskia Rösch, PhD
Saskia Rösch, PhD
Global Product Manager at Miltenyi Biotec
22 Jun 2022
36
Days
7
Hrs
16
Min
Register

Accelerating cell therapy discovery & development with non-viral gene...

D Hermanson
X Patrinostro
David Hermanson
David Hermanson
Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
Xiaobai Patrinostro
Xiaobai Patrinostro
Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne
16 Jun 2022
29
Days
15
Hrs
16
Min
Register

Applying an HPLC analytical platform for mRNA process monitoring

N Pavlin
Nejc Pavlin
Nejc Pavlin
Project Manager in Process Analytics Development at BIA Separations
7 Jun 2022
21
Days
7
Hrs
16
Min
Register

Optimizing E. Coli cell growth performance with in-line, real-time OD600...

T Buch
R Shanbaky
Tanja Buch
Tanja Buch
Technical Director at Biifactory Competence Center
Ramsey  Shanbaky
Ramsey Shanbaky
Bioprocess Applications Manger at C Technologies, Inc - a Repligen Company
1 Jun 2022
14
Days
15
Hrs
16
Min
Register

Monitoring of circulating CAR T cells

A Graband,
D Hünecke,
D Bremm
Annika Graband
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
Dr. Sabine Hünecke
Dr. Sabine Hünecke
Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
Dr. Melanie Bremm
Dr. Melanie Bremm
Deputy Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
31 May 2022
14
Days
7
Hrs
16
Min
Register